HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ

被引：0
|
作者：
E Rakovitch
S Nofech-Mozes
W Hanna
S Narod
D Thiruchelvam
R Saskin
J Spayne
C Taylor
L Paszat
机构：
[1] University of Toronto,Department of Radiation Oncology University of Toronto
[2] Sunnybrook Health Sciences Centre,Department of Pathology
[3] University of Toronto,undefined
[4] 2075 Bayview Avenue,undefined
[5] Toronto M4N 3M5,undefined
[6] Canada,undefined
[7] Institute of Clinical Evaluative Sciences,undefined
[8] University of Toronto,undefined
[9] Women's College Hospital Research Institute,undefined
[10] University of Toronto,undefined
来源：
British Journal of Cancer | 2012年 / 106卷
关键词：
DCIS; biomarkers; recurrence; breast-conserving surgery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1160 / 1165
页数：5
相关论文
共 50 条
  • [1] HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
    Rakovitch, E.
    Nofech-Mozes, S.
    Hanna, W.
    Narod, S.
    Thiruchelvam, D.
    Saskin, R.
    Spayne, J.
    Taylor, C.
    Paszat, L.
    BRITISH JOURNAL OF CANCER, 2012, 106 (06) : 1160 - 1165
  • [2] HER 2 neu over-expression predicts invasive recurrence following breast-conserving surgery for ductal carcinoma in situ of the breast (DCIS)
    Rakovitch, E.
    Pignol, J-P.
    Spayne, J.
    Nofech-Moses, S.
    Chartier, C.
    Paszat, L.
    Hanna, W.
    RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S82 - S82
  • [3] Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
    Poulakaki, Nikiforita
    Makris, Georgios-Marios
    Battista, Marco-Johannes
    Boehm, Daniel
    Petraki, Kalliopi
    Bafaloukos, Dimitrios
    Sergentanis, Theodoros N.
    Siristatidis, Charalampos
    Chrelias, Charalampos
    Papantoniou, Nikolaos
    BREAST, 2016, 25 : 57 - 61
  • [4] Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ
    Davis, James E.
    Nemesure, Barbara
    Mehmood, Saira
    Nayi, Vipul
    Burke, Stephanie
    Brzostek, Sabrina R.
    Singh, Meenakshi
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (01) : 20 - 25
  • [5] Expressions of ER, PR, Her2/neu and Ki-67 and their correlation in 55 cases of infiltrating ductal carcinoma of the breast
    Zhang, SL
    Schinella, R
    JOURNAL OF TUMOR MARKER ONCOLOGY, 2000, 15 (02): : 123 - 127
  • [6] Correlation between Ki-67 index and Her-2 Expression Status in Invasive Ductal Carcinoma of Breast
    Malik, Ayesha Imtiaz
    Kamal, Farrukh
    Basharat, Rabia
    Naz, Asima
    Iqbal, Madiha
    ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2022, 28 : 360 - 364
  • [7] The evaluation of the immunoexpression of Her2/neu oncoprotein in ductal carcinoma in situ in association with invasive ductal carcinoma of the breast
    Fota, Georgiana Luminita
    Stepan, A.
    Ciurea, Raluca Niculina
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2012, 53 (03): : 805 - 810
  • [8] Are Prognostic Factors the Same for Non-Invasive and Invasive Local Recurrence (LR) in Patients with Ductal Carcinoma In Situ (DCIS) Treated with Breast-Conserving Therapy (BCT)?
    Collins, L.
    Achacoso, N.
    Haque, R.
    Nekhlyudov, L.
    Fletcher, S.
    Quesenberry, C.
    Schnitt, S.
    Habel, L.
    LABORATORY INVESTIGATION, 2011, 91 : 34A - 34A
  • [9] Are Prognostic Factors the Same for Non-Invasive and Invasive Local Recurrence (LR) in Patients with Ductal Carcinoma In Situ (DCIS) Treated with Breast-Conserving Therapy (BCT)?
    Collins, L.
    Achacoso, N.
    Haque, R.
    Nekhlyudov, L.
    Fletcher, S.
    Quesenberry, C.
    Schnitt, S.
    Habel, L.
    MODERN PATHOLOGY, 2011, 24 : 34A - 34A
  • [10] The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast
    Latta, EK
    Tjan, S
    Parkes, RK
    O'Malley, FP
    MODERN PATHOLOGY, 2002, 15 (12) : 1318 - 1325
12345